Nalbuphine is a Mu-opioid-receptor antagonist and a Kappa-opioid-receptor agonist. Therefore it is an opioid antagonist which is - nevertheless - having a high analgesic potential via the kappa-opioid-receptors. Nalbuphine has the big advantage that it is not causing a respiratory depression like pure Mu-opioid-receptor agonists like Morphine or Fentanyl etc. Nalbuphine is indicated for the relief of moderate to severe pain and can also be used as a supplement to balanced anaesthesia, for preoperative and postoperative analgesia (sequential analgesia), and for obstetrical analgesia during contraction pains and delivery (no negative impact on the baby because of the ceiling effect on respiratory depression). Target groups are above all anaesthetists and hospitals. Nalbuphine is not a scheduled opioid and therefore very easy to handle. Granted Marketing Authorisations are available in Europe. EU eCTD dossier available. Generic version.
Country-specific or regional distribution contract.